Epstein-Barr virus nuclear antigen 1-derived peptide–Major Histocompatibility Complex class I complex (EBV EBNA1-pMHC I)

The Epstein-Barr virus nuclear antigen 1 (EBNA1)-derived peptide–Major Histocompatibility Complex (MHC) class I complex is a specialized immunological target for the treatment of EBV-associated malignancies. EBNA1 is a multifunctional protein required for the replication and maintenance of the EBV genome in host cells (PMID: 21835161). Although EBNA1 contains a glycine-alanine repeat (GAr) domain that inhibits its own proteasomal degradation to evade immune detection (PMID: 7753198), research has demonstrated that specific EBNA1 peptides are successfully processed and presented on MHC class I molecules (PMID: 15153531). These complexes, such as those involving the HLA-A*02:01 restricted peptide VLKDAIKDL, serve as highly specific markers for EBV-infected or transformed cells (PMID: 30305453). Therapeutic interventions targeting these complexes include T-cell receptor (TCR)-like antibodies and TCR-engineered T-cells, which can bypass viral evasion mechanisms to induce direct cytotoxic killing of tumor cells (PMID: 33441364). This target is particularly relevant for diseases like nasopharyngeal carcinoma and EBV-positive lymphomas where EBNA1 is consistently expressed (PMID: 24171985). Current drug development focuses on improving the affinity and specificity of these agents to minimize off-target effects while maximizing anti-tumor efficacy (PMID: 33441364).

Other names

EBNA1-pMHCEBNA1-HLA complexEBNA1 peptide-MHC class IEBV EBNA1-MHC I

Targeted recognition by T-cell receptors or TCR-mimetic antibodies to induce cytotoxic T-lymphocyte mediated lysis of EBV-positive cells.